Information Provided By:
Fly News Breaks for October 18, 2019
Oct 18, 2019 | 07:08 EDT
H.C. Wainwright analyst Oren Livnat initiated coverage of Menlo Therapeutics with a Buy rating and $11 price target. The analyst expects prurigo nodularis Phase 3 topline data in the first half of 2020, and projects 2021 approval and peak $300M U.S. sales. The recent dermatology disappointments "don't doom Menlo," says the analyst.
News For MNLO From the Last 2 Days
There are no results for your query MNLO